Literature DB >> 9664159

Biologic effects and potential clinical applications of Flt3 ligand.

S D Lyman1.   

Abstract

Flt3 ligand (FL) is a member of a small family of growth factors that stimulate the proliferation of hematopoietic cells by binding to and activating distinct tyrosine kinase receptors. Other members of this family include M-CSF and the c-kit ligand. Expression of the Flt3 receptor is primarily restricted to the most primitive hematopoietic progenitor cells, and FL stimulates the proliferation in vitro and the expansion and mobilization in vivo of stem and progenitor cells. FL as a single factor has little proliferative activity on these stem and progenitor cells, but it synergizes with a wide range of other colony-stimulating factors and interleukins to stimulate proliferation of these cells. FL is also an effective agent for mobilizing stem and progenitor cells to peripheral blood. Recent data demonstrating anti-tumor activity of FL suggest that this protein plays a major role in activating the immune system via its ability to stimulate the production of both dendritic and natural killer cells. These biologic activities of FL may potentially prove quite useful in a number of clinical settings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664159     DOI: 10.1097/00062752-199805000-00008

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  6 in total

1.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

2.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

Review 3.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

4.  Barley as a green factory for the production of functional Flt3 ligand.

Authors:  Lýdur S Erlendsson; Marcus O Muench; Ulf Hellman; Soffía M Hrafnkelsdóttir; Anders Jonsson; Yves Balmer; Einar Mäntylä; Björn L Orvar
Journal:  Biotechnol J       Date:  2010-02       Impact factor: 4.677

5.  Spontaneous circulation of myeloid-lymphoid-initiating cells and SCID-repopulating cells in sickle cell crisis.

Authors:  Christopher E D Lamming; Lance Augustin; Mark Blackstad; Troy C Lund; Robert P Hebbel; Catherine M Verfaillie
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.

Authors:  Megan S Molina; Emely A Hoffman; Jessica Stokes; Nicole Kummet; Kyle A Smith; Forrest Baker; Tiffany M Zúñiga; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.